4 entries found for : it-83
Worked to the bone: antibody-based conditioning as the future of transplant biology
Griffin JM, Healy FM, Dahal LN, Floisand Y, Woolley JF (2022) Worked to the bone: antibody-based conditioning as the future of transplant biology. J Hematol Oncol 15(1):65. doi: 10.1186/s13045-022-01284-6
Objective: To analyze the current status of antibody-based drugs in pre-transplant conditioning regimens and assess their potential in the future of transplant biology.
Summary: This review article suggests that antibody-based conditioning regimens may be the next big advancement in hematopoietic stem cell transplantation.
Related Products: Anti-CD117-SAP (Cat. #IT-83)
See Also:
- Palchaudhuri R et al. Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nat Biotechnol 34:738-745, 2016.
- Castiello MC et al. Efficacy and safety of anti-CD45-saporin as conditioning agent for RAG deficiency. J Allergy Clin Immunol 147(1):309-320.e6, 2021.
- Czechowicz A et al. Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. Nat Commun 10:617, 2019.
- Li Z et al. Hematopoietic chimerism and donor-specific skin allograft tolerance after non-genotoxic CD117 antibody-drug-conjugate conditioning in MHC-mismatched allotransplantation. Nat Commun 10:616, 2019.
Immunological barriers to haematopoietic stem cell gene therapy
Charlesworth CT, Hsu I, Wilkinson AC, Nakauchi H (2022) Immunological barriers to haematopoietic stem cell gene therapy. Nat Rev Immunol 1-15. doi: 10.1038/s41577-022-00698-0
Objective: This review article attempts to encourage more research to address the immunological barriers to haematopoietic stem cell based gene therapies.
Summary: The authors lay out the history and clinical trials of hematopoietic stem cell gene therapy and then discuss the challenges of both innate immunity and adaptive immunity.
Usage: This review mentions a publication that used Anti-CD117-SAP to ablate hematopoietic stem cells.
Related Products: Anti-CD117-SAP (Cat. #IT-83)
See Also:
The biology of hematopoietic stem cells and its clinical implications
Skulimowska I, Sosniak J, Gonka M, Szade A, Jozkowicz A, Szade K (2021) The biology of hematopoietic stem cells and its clinical implications. FEBS J 16192. doi: 10.1111/febs.16192Objective: To review the opportunities and challenges of recent findings to improve the clinical use of hematopoietic stem cells (HSCs)
Summary: The authors describe new methods of HSC mobilization and conditioning for transplantation and highlight research that may lead to solutions for the limitations of HSC transplantation
Read the featured article in Targeting Trends.
Related Products: Anti-CD117-SAP (Cat. #IT-83)
Czechowicz A, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Pang WW, Mansour MK, Tate TA, Chan YY, Walck E, Wernig G, Shizuru JA, Winau F, Scadden DT, Rossi DJ (2019) Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. Nat Commun 10:617. doi: 10.1038/s41467-018-08201-xObjective: To investigate a safe and effective method for hematopoietic stem cell transplantation.
Summary: CD117-ADC selectively targets hematopoietic stem cells yet does not cause clinically significant side-effects.
Usage: The CD117-ADC was prepared by combining biotinylated anti-CD117 (clone 2B8) with Streptavidin–ZAP. A dose of 1.5 mg/kg of CD117-ADC (~12 µg Streptavidin-ZAP) optimally resulted in depletion of >99% of immunophenotypic and functional HSCs.
Related Products: Streptavidin-ZAP (Cat. #IT-27), Anti-CD117-SAP (Cat. #IT-83)